We are live on ! Find out more
TBRA

Tobira Therapeutics, Inc. Common Stock
TBRA

Delisted

TBRA was delisted on the 31st of October, 2016.

68 hedge funds and large institutions have $505M invested in Tobira Therapeutics, Inc. Common Stock in 2016 Q3 according to their latest regulatory filings, with 36 funds opening new positions, 20 increasing their positions, 5 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

300% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 5

244% more capital invested

Capital invested by funds: $147M → $505M (+$358M)

177% more first-time investments, than exits

New positions opened: 36 | Existing positions closed: 13

51% more funds holding

Funds holding: 4568 (+23)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

72% less call options, than puts

Call options by funds: $1.18M | Put options by funds: $4.17M

Holders
68
Holders Change
+23
Holders Change %
+51.11%
% of All Funds
1.81%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.08%
New
36
Increased
20
Reduced
5
Closed
13
Calls
$1.18M
Puts
$4.17M
Net Calls
-$3M
Net Calls Change
-$3M
Name Holding Trade Value Shares
Change
Change in
Stake
NC
76
Nexthera Capital
New York
-$942K -75,000 Closed
William Blair & Company
77
William Blair & Company
Illinois
-$253K -20,115 Closed
OAM
78
Oxford Asset Management
United Kingdom
-$189K -15,028 Closed
DCM
79
Driehaus Capital Management
Illinois
-$140K -11,135 Closed
Simplex Trading
80
Simplex Trading
Illinois
-$25.7K -2,302 Closed
PNC Financial Services Group
81
PNC Financial Services Group
Pennsylvania
-$1K -68 Closed

TBRA Hedge Fund Activity: Q3 2016 in Review

68 of the 3,748 institutional investors tracked by Wall St. Rank reported a position in Tobira Therapeutics, Inc. Common Stock (TBRA) for Q3 2016, worth a combined $505M — up 244% from $147M a quarter earlier.

Buyers outnumbered sellers: 36 funds opened new TBRA positions and 13 closed out — a net gain of 23 holders — while 20 added to existing stakes and 5 trimmed.

The largest buyer was Pentwater Capital Management, opening a new position worth an estimated $41.3M. The largest seller was Novo Holdings A/S, exiting entirely with an estimated $25.5M sold.

  • 68 institutional investors held Tobira Therapeutics, Inc. Common Stock (TBRA) as of Q3 2016, up from 45 in Q2 2016.
  • Funds reported $505M of Tobira Therapeutics, Inc. Common Stock stock for Q3 2016, up 244% quarter-over-quarter.
  • 36 funds opened new Tobira Therapeutics, Inc. Common Stock positions in Q3 2016 and 13 closed out, a net change of +23 holders.
  • The largest Tobira Therapeutics, Inc. Common Stock buyer in Q3 2016 was Pentwater Capital Management, an estimated $41.3M added.
  • The largest Tobira Therapeutics, Inc. Common Stock seller in Q3 2016 was Novo Holdings A/S, an estimated $25.5M sold.

Based on aggregated 13F filings for Q3 2016.